Adaptimmune Therapeutics (ADAP) Q3 2024 earnings summary

Executive summary

• Announced a new strategic business plan focused on streamlining operations, prioritizing high-return R&D, and targeting operating break-even by 2027, with a 33% headcount reduction and $300 million in cost savings over four years.

• FDA approved Tecelra, the first engineered cell therapy for solid tumors, with commercial launch underway and 9 treatment centers active, aiming for 30 by end of 2025.

• Lete-cel pivotal trial reported a 42% response rate in synovial sarcoma and MRCLS, supporting a BLA filing planned for 2025.

• Projected $400 million in combined U.S. peak revenue for Tecelra and lete-cel, with lete-cel expected to comprise over 60% of franchise revenue.

• Collaboration with Galapagos for uza-cel in head and neck cancer continues, while non-core programs, including ovarian cancer, are being discontinued.

Financial highlights

• Q3 2024 revenue was $40.9 million, up from $7.3 million in Q3 2023, mainly due to Genentech agreement termination and related payments; nine-month revenue rose to $174.8 million.

• Net loss for Q3 2024 was $17.6 million, an improvement from $45.6 million loss in Q3 2023; nine-month net profit was $3.4 million.

• Ended Q3 2024 with $186.1 million in total liquidity, including $116.7 million in cash and equivalents.

• $49.5 million drawn from Hercules Capital loan facility in 2024; $29.2 million raised from ATM equity offering.

• R&D expenses for Q3 2024 were $34.3 million; SG&A expenses were $21.2 million.

Outlook and guidance

• Targeting operating cash flow break-even in 2027, with substantial cost savings reducing future financing needs.

• First commercial revenues from Tecelra expected in Q4 2024, with acceleration as the treatment center network expands.

• Combined U.S. peak year sales for Tecelra and lete-cel projected at $400 million.

• Management expects current liquidity to fund operations for at least 12 months, but additional capital will be required for long-term operations.

• Rolling BLA submission for lete-cel planned by end of 2025.